Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 14/20 | 0.50 |
| ▸ | HTR7 | P34969 | 12/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.50 |
| ▸ | SLC9A1 | P19634 | 3/20 | 0.39 |
| ▸ | HTR5A | P47898 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2262243 | 0.93 | HTR2B (0.52) | HTR2BHTR7DRD2ADRA1DHTR2A | |
| SCHEMBL12366958 | 0.85 | HTR2B (0.40) | HTR2BHTR7DRD2ADRA1DHTR2A | |
| SCHEMBL12366962 | 0.85 | HTR2B (0.50) | HTR2BHTR7DRD2ADRA1DHTR2A | |
| SCHEMBL12365280 | 0.83 | ALDH1A1 (0.49) | — | |
| SCHEMBL12366655 | 0.83 | HTR2B (0.46) | HTR2BHTR7DRD2ADRA1DHTR2A | |
| SCHEMBL12366680 | 0.83 | HTR2B (0.55) | HTR2BHTR7DRD2ADRA1DHTR2A | |
| SCHEMBL12389908 | 0.82 | HTR2B (0.47) | HTR2BHTR7DRD2ADRA1DHTR2A | |
| SCHEMBL12366723 | 0.82 | HTR2B (0.45) | HTR2BHTR7DRD2ADRA1DHTR2A | |
| SCHEMBL12366721 | 0.81 | HTR2B (0.45) | HTR2BHTR7DRD2ADRA1DHTR2A | |
| SCHEMBL12366693 | 0.81 | HTR2B (0.45) | HTR2BHTR7DRD2ADRA1DHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-08-25 | — | — | US | disclosed |
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-08-25 | — | — | US | disclosed |
| EP-2177505-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2010-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | HTR2B 7/4885HTR7 13/4885DRD2 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.